A cyclooxygenase‐2 inhibitor, nimesulide, inhibits postinitiation phase of N‐nitrosobis(2‐oxopropyl)amine‐induced pancreatic carcinogenesis in hamsters
Open Access
- 4 February 2003
- journal article
- carcinogenesis
- Published by Wiley in International Journal of Cancer
- Vol. 104 (3) , 269-273
Abstract
The modification effects of nimesulide, a cyclooxygenase (COX)‐2 inhibitor, administration during the postinitiation phase of pancreatic carcinogenesis were investigated in hamsters treated with N‐nitrosobis(2‐oxopropyl)amine (BOP). Male Syrian hamsters were given 4 weekly s.c. injections of BOP at a dose of 10 mg/kg and thereafter administered 0, 100 or 400 ppm nimesulide in the diet for 36 weeks. Additional groups of hamsters were fed 400 ppm nimesulide without prior BOP initiation or nontreated. At week 40, all surviving animals were killed and development of neoplastic and preneoplastic lesions was assessed histopathologically. The incidence of pancreatic adenocarcinomas was significantly (p < 0.05) decreased in the BOP/400 ppm nimesulide group compared to the BOP alone group. The multiplicity of total lesions of pancreatic adenocarcinoma plus atypical hyperplasia was also significantly (p < 0.05) lowered. Immunohistochemically, COX‐2 was clearly expressed in pancreatic and lung tumor cells, whereas expression was not remarkably affected by the 400 ppm nimesulide treatment. Proliferating cell nuclear antigen labeling indices of pancreatic ducts were significantly (p < 0.01) reduced by nimesulide. The incidence and multiplicity of neoplastic lesions in other organs did not significantly differ among the BOP‐treated groups, though only the multiplicity of lung tumors showed a tendency to decrease. No neoplastic lesions were detected in animals receiving nimesulide alone. Our results clearly indicate that nimesulide protects against BOP‐induced pancreatic tumors in hamsters.Keywords
This publication has 25 references indexed in Scilit:
- Association Between Nonsteroidal Anti-Inflammatory Drug Use and the Incidence of Pancreatic CancerJNCI: Journal of the National Cancer Institute, 2002
- Cyclooxygenase 2 Expression in Pancreatic Adenocarcinoma and Pancreatic Intraepithelial NeoplasiaAmerican Journal of Clinical Pathology, 2002
- Chemoprevention by Nimesulide, a Selective Cyclooxygenase‐2 Inhibitor, of 2‐Amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP)‐induced Mammary Gland Carcinogenesis in RatsJapanese Journal of Cancer Research, 2000
- Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in NeoplasiaCritical Reviews in Clinical Laboratory Sciences, 2000
- Antioxidant Agent Nimesulid and β-Blocker Metoprolol Do Not Exert Protective Effects against Rat Mitochondrial DNA Alterations in Adriamycin-Induced CardiotoxicityBiochemical and Biophysical Research Communications, 1999
- Japan Pancreatic Cancer RegistryPancreas, 1998
- Mechanistic Insights into Chemopreventive Effects of Phenethyl Isothiocyanate in N‐Nitrosobis(2‐oxopropyl)amine‐treated HamstersJapanese Journal of Cancer Research, 1997
- Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2Journal of Cancer Research and Clinical Oncology, 1996
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995
- Prostaglandin E2 Down-Regulates the Expression of HLA-DR Antigen in Human Colon Adenocarcinoma Cell LinesBiochemistry, 1995